Blog Archives

Blog

Breaking New Ground: EMA Qualification of the Simcyp® Simulator Ushers in a New Era for PBPK Modeling

The Simcyp Simulator receives EMA qualification—the first and only PBPK platform formally qualified for any…

CertaraAugust 5, 2025

Blog

Machine Learning (ML) in healthcare

Learn about 3 distinct examples of machine learning (ML) in healthcare that utilize different techniques…

CertaraAugust 1, 2025

Blog

Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials

GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…

CertaraJuly 31, 2025

Blog

Recapping a record-breaking 2025 Krakow HTA Symposium

We cover the key takeaways from CERTAINTY 2025, including the power of Model-Informed Drug Development…

Simona ColucciJuly 30, 2025

Blog

Scanning research collections against generic definitions

A case study of finding substances controlled by generic definitions in a chemical library with…

CertaraJuly 30, 2025

Blog

Challenges in implementing a reliable highly-similar detection algorithm

Dive into the challenges of creating a reliable algorithm for detecting controlled substance analogues and…

CertaraJuly 30, 2025

Blog

Introduction to Controlled Substance Analogues and Generic Definitions

Learn everything there is about controlled substance analogues, generic definitions and the evolution of controlled…

CertaraJuly 30, 2025

Blog

How Pharma Can Transition to Non-animal Studies for Investigational Drugs

Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…

CertaraJuly 25, 2025

Blog

ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered

ADNCA is transforming non-compartmental analysis by standardizing workflows, enhancing regulatory confidence, and enabling scalable automation.…

CertaraJuly 23, 2025

Blog

MIDD can ease pediatric & rare disease drug loss in Japan

Certara tackles pediatric cancer and rare disease drug loss in Japan by advocating MIDD, which…

CertaraJuly 8, 2025

Blog

Breaking New Ground: EMA Qualification of the Simcyp® Simulator Ushers in a New Era for PBPK Modeling

Machine Learning (ML) in healthcare

Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials

Recapping a record-breaking 2025 Krakow HTA Symposium

Scanning research collections against generic definitions

Challenges in implementing a reliable highly-similar detection algorithm

Introduction to Controlled Substance Analogues and Generic Definitions

How Pharma Can Transition to Non-animal Studies for Investigational Drugs

ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered

MIDD can ease pediatric & rare disease drug loss in Japan

Newsletter sign up

Quick links

Solutions

Contact